PharmaMar's profits rebound with a 64% increase to 2.3 million euros in Q1 2024 compared to the same period last year. Total revenues dropped by 19.45%...
PharmaMar started February with falls of almost 3% at the opening of the market. The reason was that Sylentis had failed in its primary objective of...
PharmaMar is a biopharmaceutical company based in Madrid, specializing in the discovery, development, and commercialization of new antitumor drugs of marine origin. The company has a...
PharmaMar wanted to highlight the growth in royalty income, which has increased by 8% compared to the same period of the previous year, reaching a total...
The company has confirmed that, as a result of its commitment to R&D in oncology, it has achieved a success rate of 37% in its research, compared...
The Spanish pharma sector increased 5% on the stock market in the first quarter despite the fall of Grifols. Pharma Mar was the pharmaceutical company with...